Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shkreli’s Retrophin Gets Another Injection Of Capital; Talks Up Clinical Plans

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech, founded in late 2011 by venture capitalist Martin Shkreli, has yet to make any significant clinical moves with the compounds in its pipeline, but signs show that could change before year-end.


Related Content

Deals Of The Week: GSK’s Stealth Move To The Coasts
In One Stroke, Retrophin Acquires And Licenses Assets For Autism And Schizophrenia, Doubles Down On Oxytocin
Start-Up Quarterly Statistics, Q3 2013
Financings Of The Fortnight Checks The Corporate Venture Numbers
Duchenne Muscular Dystrophy: Pipeline And Partnering Snapshot
Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos
Hedge Fund MSMB Offers to Buy AMAG For $381M and Thwart Proposed Allos Merger


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts